Centessa Pharmaceuticals (CNTA) Accounts Payables (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Accounts Payables data on file, last reported at $10.7 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $10.7 million, up 107.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.7 million (up 107.68% YoY), and the FY2025 annual result was $7.6 million, up 6.15% from the prior year.
• Accounts Payables climbed to $10.7 million in Q1 2026 per CNTA's latest filing, from $7.6 million in the prior quarter.
• Over five years, Accounts Payables peaked at $14.4 million in Q1 2023 and troughed at $5.1 million in Q1 2025.
• A 5-year average of $9.0 million and a median of $8.2 million in 2022 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables surged 114.8% in 2023, then plunged 52.01% in 2024.
• A 5-year view of Accounts Payables shows it stood at $13.8 million in 2022, then declined by 14.61% to $11.8 million in 2023, then plunged by 39.54% to $7.1 million in 2024, then increased by 6.15% to $7.6 million in 2025, then jumped by 40.57% to $10.7 million in 2026.
• Business Quant data shows CNTA's Accounts Payables at $10.7 million in Q1 2026, $7.6 million in Q4 2025, and $8.7 million in Q3 2025.